Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 74.5%

Neg 0% Neu 0% Pos 74.5%

Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.